{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:16Z","timestamp":1793403736437,"version":"4.5.0"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antifibrotic agents slow disease progression and improve survival in IPF, yet real-life data on their use in Turkey are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to compare the side effects of antifibrotics in IPF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A cross-sectional survey was conducted in 8 centers across 6 provinces in the Aegean Region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>There were 470 IPF patients who completed a 30-item face-to-face questionnaire. Adverse events and their management were compared between pirfenidone and nintedanib users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 470 patients, 50.6% used pirfenidone and 49.4% nintedanib. Overall, 70.6% reported at least one side effect (75.5% nintedanib vs. 66% pirfenidone, p=0.023). Medical treatment was required in 30.9% and dose reduction in 18.9%. The most common side effects were diarrhea (30.6%), appetite loss (24.9%), and nausea (22.3%). Diarrhea (p&lt;0.001) and weight loss (p=0.010) were more frequent with nintedanib, while rash, photosensitivity, and fatigue were more common with pirfenidone (all p&lt;0.001). Nausea, vomiting, appetite loss, and fatigue were more frequently reported in women, and vomiting, anorexia, and rash were more frequently observed in patients with comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adverse events are frequent in IPF patients receiving antifibrotics. Nintedanib mainly causes gastrointestinal symptoms, whereas pirfenidone leads to skin reactions and fatigue. Female sex and the presence of comorbidities were associated with a higher frequency of certain adverse events. Supportive treatment and dose adjustments are crucial for maintaining adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666261475558","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:08Z","timestamp":1788193508000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported adverse events and management of antifibrotic therapy in IPF: A multicenter, cross-sectional real-world study"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-0470","authenticated-orcid":false,"given":"Onur","family":"Turan","sequence":"first","affiliation":[{"name":"Izmir Katip Celebi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"U\u011furlu","sequence":"additional","affiliation":[{"name":"Pamukkale University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Oral Tapan","sequence":"additional","affiliation":[{"name":"Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Sar\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Bal\u0131kesir University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclru","family":"Polat","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Suat Seren Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eule","family":"\u00c7ilekar","sequence":"additional","affiliation":[{"name":"Pulmonology Department, AFSU Health and Application Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Batum","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Izmir Bayrakl\u0131 City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eule Ta\u015f","family":"G\u00fclen","sequence":"additional","affiliation":[{"name":"Ayd\u0131n Adnan Menderes University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.3-b.s17"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.014"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02593-2017"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.581828"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-019-00260-1"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03198-2020"},{"issue":"1","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"e001687","DOI":"10.1136\/bmjresp-2023-001687","article-title":"Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study","volume":"11","author":"Romero Ortiz AD","year":"2024","unstructured":"Romero Ortiz AD, Jim\u00e9nez-Rodr\u00edguez BM, L\u00f3pez-Ram\u00edrez C, et al. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study. BMJ Open Respir Res 2024; 11(1): e001687. https:\/\/doi.org\/10.1136\/bmjresp-2023-001687","journal-title":"BMJ Open Respir Res"},{"key":"e_1_3_8_11_2","volume-title":"VigiAccess\u2122 [Internet]","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. VigiAccess\u2122 [Internet], 2024. [cited 2024 Apr 10]. Available from: https:\/\/www.vigiaccess.org\/"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262795"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"issue":"2","key":"e_1_3_8_14_2","first-page":"e54268","article-title":"A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review","volume":"16","author":"Man RK","year":"2024","unstructured":"Man RK, Gogikar A, Nanda A, et al. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review. Cureus 2024; 16(2): e54268. https:\/\/doi.org\/10.7759\/cureus.54268","journal-title":"Cureus"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0238-2024"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2023.04.007"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019862497"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2020.101917"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2017"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102099"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305429"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261475558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666261475558","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261475558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:49:29Z","timestamp":1788367769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666261475558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"alternative-id":["10.1177\/17534666261475558"],"URL":"https:\/\/doi.org\/10.1177\/17534666261475558","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666261475558\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v4\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261475558\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17534666261475558"}}